Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OP-3136 |
| Synonyms | |
| Therapy Description |
OP-3136 is a selective KAT6 inhibitor, which potentially inhibits tumor cell proliferation and decreases tumor growth (European Journal of Cancer 211 (2024): 114748). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OP-3136 | OP 3136|OP3136 | OP-3136 is a selective KAT6 inhibitor, which potentially inhibits tumor cell proliferation and decreases tumor growth (European Journal of Cancer 211 (2024): 114748). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06784193 | Phase I | Fulvestrant + OP-3136 OP-3136 + Palazestrant OP-3136 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |